Inhibition of If in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation

Heart Rhythm

Volumn 10, Issue 11, 2013, Pages 1692-1697

  Verrier, Richard L ^a,b   Sobrado, Marcel F ^a,c   Pagotto, Vitor P F ^a,c   Kanas, Alexandre F ^a,c   Machado, Ananda D ^a,c   Varone, Bruno B ^a,c   Sobrado, Lucas F ^a,c   Nearing, Bruce D ^a,b   Zeng, Dewan ^d   Belardinelli, Luiz ^d  

^a Beth Israel Deaconess Medical Center   (Israel)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d GILEAD SCIENCES   (United States)

Author keywords

Atrial fibrillation; Atrioventricular node; Dronedarone; Human hyperpolarization activated cyclic nucleotide gated (HCN) channel; If inhibition; Ivabradine

Indexed keywords

ACETYLCHOLINE; DRONEDARONE; IVABRADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TISSUE LEVEL; EXPERIMENTAL PIG; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART MUSCLE REFRACTORY PERIOD; HEART RATE; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; TREATMENT RESPONSE;

A-H; ACETYLCHOLINE; ACH; AERP; AF; ATRIAL EFFECTIVE REFRACTORY PERIOD; ATRIAL FIBRILLATION; ATRIAL-HIS; ATRIOVENTRICULAR; ATRIOVENTRICULAR NODE; AV; DRONEDARONE; ECG; ELECTROCARDIOGRAM; HHCN4; HUMAN HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED (HCN) CHANNEL; HUMAN HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 4; I(F) INHIBITION; INTRAVENOUS; IV; IVABRADINE; MAP; MEAN ARTERIAL PRESSURE; RA; RIGHT ATRIAL; VENTRICULAR EFFECTIVE REFRACTORY PERIOD; VERP;

AMIODARONE; ANIMALS; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; BENZAZEPINES; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HEART RATE; HEART VENTRICLES; MALE; SWINE; VENTRICULAR FUNCTION, LEFT;

EID: 84887024357     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2013.08.007     Document Type: Article

References (26)

1. H. Calkins, J. Brugada, and D.L. Packer HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up Heart Rhythm 4 2007 816 861
2. C. Patel, G.X. Yan, and P.R. Kowey Dronedarone Circulation 120 2009 636 644
3. B.N. Singh, S.J. Connolly, and H.J. Crijns Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter N Engl J Med 357 2007 987 999
4. S.H. Hohnloser, HJGM Crijns, and M. van Eickels for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation N Engl J Med 360 2009 668 678
5. R.L. Page, S.J. Connolly, and H.J. Crijns for the ATHENA Investigators. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial) Am J Cardiol 107 2011 1019 1022
6. J.M. Davy, M. Herold, and C. Hoglund Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study Am Heart J 156 2008 527 529
7. S.J. Connolly, A.J. Camm, and J.L. Halperin for the PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation N Engl J Med 365 2011 2268 2276
8. 2+ and HCN channels Naunyn Schmiedebergs Arch Pharmacol 383 2011 347 356
9. f current J Cardiovasc Electrophysiol 24 2013 914 918
10. A.A. Munk, R.A. Adjemian, J. Zhao, A. Ogbaghebriel, and A. Shrier Electrophysiological properties of morphologically distinct cells isolated from the rabbit atrioventricular node J Physiol 493 1996 801 818
11. W. Shi, R. Wymore, and H. Yu Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues Circ Res 85 1999 e1 e6
12. H. Dobrzynski, V.P. Nikolski, and A.T. Sambelashvili Site of origin and molecular substrate of atrioventricular junctional rhythm in the rabbit heart Circ Res 93 2003 1102 1110
13. D. Di Francesco The role of the funny current in pacemaker activity Circ Res 106 2010 434 446
14. f inhibitor, in the anesthetized dog heart J Cardiovasc Pharmacol 26 1995 957 964
15. V. Chiamvimonvat, D. Newman, and A. Tang A double-blind placebo-controlled evaluation of the human electrophysiologic effects of zatebradine, a sinus node inhibitor J Cardiovasc Pharmacol 32 1998 516 520
16. K. Kumar, B.D. Nearing, and M. Carvas Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart J Cardiovasc Electrophysiol 20 2009 796 802
17. T.H. Everett, L.C. Kok, R.H. Vaughn, J.R. Moorman, and D.E. Haines Frequency domain algorithm for quantifying atrial fibrillation organization to increase defibrillation efficacy IEEE Trans Biomed Eng 48 2001 969 978
18. J.M. Van Opstal, M. Schoenmakers, and S.C. Verduyn Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome Circulation 104 2001 2722 2727
19. O. Finance, A. Manning, and P. Chatelain Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs J Cardiovasc Pharmacol 26 1995 570 576
20. K. Fox, I. Ford, P.G. Steg, M. Tendera, and R. Ferrari for the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
21. A. Manning, V. Thisse, D. Hodeige, J. Richard, J.P. Heyndrickx, and P. Chatelain SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs J Cardiovasc Pharmacol 25 1995 252 261
22. Kr blocker, on the atrioventricular node in anesthetized dog hearts Eur J Pharmacol 297 1996 233 239
23. M. Baruscotti, A. Barbuti, and A. Bucchi The cardiac pacemaker current J Mol Cell Cardiol 48 2010 55 64
24. 2+ cycling J Mol Cell Cardiol 62 2013 80 89
25. C. Thollon, S. Bedut, and N. Villeneuve Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity Br J Pharmacol 150 2007 37 46
26. R.H. Cox Influence of chloralose anesthesia on cardiovascular function in trained dogs Am J Physiol 223 1972 660 667